carboplatin increases responses in NAC in women with triple negative breast cancer

it seems clear through multiple studies that carboplatin improves the pCR (pathological complete response rate) in women having NAC (neoadjuvant or preoperative chemotherapy) in the setting of triple negative breast cancer.

It clearly adds toxicity through low white cells, and it remains unclear whether the benefit increases the chance of cure. The jury is still out but certainly could be considered in circumstances where the cancer is not initally responding well to standard therapy.